Drug Trial Radar · NCT05196477
Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection
Last checked: Nov 20, 2026Latest source record: Jan 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,087
Actual
Start
Jul 14, 2021
Primary completion
Aug 29, 2022
Study completion Aug 29, 2022
Sponsor
- Lead sponsor
- R-PharmIndustry
- Sponsor type
- Industry
- Collaborators
- Almedis LLC; Data Management 365; ScienceFiles LLC
- First posted
- Jan 19, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study purpose was to assess the outcomes of therapy with olokizumab within complex therapy of Coronavirus disease 2019 (COVID-19) in hospitalised patients in real clinical practice setting. The study investigated patients' characteristics, disease progression, and efficacy and safety of olokizumab therapy.
Conditions
- COVID-19
Interventions
OlokizumabDrug
The details of taking olokizumab, including its route of administration, dose and frequency of taking the drug as part of routine clinical practice, will be registered in the electronic case report forms (eCRFs).
Standard therapyDrug
Standard treatment (excluding administration of olokizumab, other interleukin (IL) (interleukin-1 and interleukin-17) inhibitors and Janus-kinase inhibitors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The percentage of patients who died during hospital admission due to any reasonTime frame: up to 21 days
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
State Budgetary Healthcare Institution "Regional Hospital № 3"
Chelyabinsk, Russia
State Budgetary Healthcare Institution "City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department"
Moscow, Russia
St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 40 of the Kurortny District"
Saint Petersburg, Russia
State Budgetary Institution of Healthcare of Tver region "Regional clinical hospital"
Tver', Russia
Federal State Budgetary Educational Institution of Higher Education "Kazan State Medical University" under the Ministry of Health of the Russian Federation
Kazan', Tatarstan Republic, Russia
Federal State Budgetary Educational Institution of Higher Education Bashkir State Medical University of the Ministry for Healthcare of the Russian Federation
Ufa, The Republic of Bashkortostan, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.